ArticleFrontiers in oncology2021
Multiparameter MRI Model With DCE-MRI, DWI, and Synthetic MRI Improves the Diagnostic Performance of BI-RADS 4 Lesions.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Multiparametric MRI for non-mass enhancement breast lesions: a prospective diagnostic accuracy study.European radiology · 2026Article
- SynQ-Breast: a flexible deep learning framework for quantitative MRI of breast tumors via synthetic data with IVIM-MRI validation.Quantitative imaging in medicine and surgery · 2026Article
- Delta Histogram Analysis of Synthetic MRI for Evaluating Grade and Cellular Proliferation of Meningioma.Radiology. Imaging cancer · 2026Article
- The role of magnetic resonance imaging (MRI) in breast cancer molecular subtypes.Polish journal of radiology · 2026Review
- A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer.Frontiers in oncology · 2026Article
- Histogram analysis of relaxometry from synthetic MRI for differentiation of breast BI-RADS 4 non-mass enhancement lesions.BMC medical imaging · 2025Article
- Quantitative MR Imaging of the Breast.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Prospective evaluation of mpMRI-derived nomograms for detecting prostate cancer in PI-RADS v2.1 upgraded and non-upgraded lesions.Frontiers in oncology · 2025Article
- Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging.Breast cancer research : BCR · 2024Article
- Analysis of the Value of Quantitative Features in Multimodal MRI Images to Construct a Radio-Omics Model for Breast Cancer Diagnosis.Breast cancer (Dove Medical Press) · 2024Article
- Case Report: Efficacy of Multiparameter MRI in Diagnosis of Chronic Breast Inflammation Complicated with Invasive Ductal Carcinoma and Ductal Carcinoma in situ.Cancer management and research · 2024Article
- The utility of diffusion-weighted imaging for differentiation of phyllodes tumor from fibroadenoma and breast cancer.Frontiers in oncology · 2023Article
- The road to breast cancer screening with diffusion MRI.Frontiers in oncology · 2023Review
- Combination of ultrafast dynamic contrast-enhanced MRI-based radiomics and artificial neural network in assessing BI-RADS 4 breast lesions: Potential to avoid unnecessary biopsies.Frontiers in oncology · 2023Article
- Identification of the Benignity and Malignancy of BI-RADS 4 Breast Lesions Based on a Combined Quantitative Model of Dynamic Contrast-Enhanced MRI and Intravoxel Incoherent Motion.Tomography (Ann Arbor, Mich.) · 2022Article
- Evaluation of the differentiation of benign and malignant breast lesions using synthetic relaxometry and the Kaiser score.Frontiers in oncology · 2022Article
- Synthetic MRI, multiplexed sensitivity encoding, and BI-RADS for benign and malignant breast cancer discrimination.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the value of synthetic magnetic resonance imaging (syMRI), diffusion-weighted imaging (DWI), DCE-MRI, and clinical features in breast imaging-reporting and data system (BI-RADS) 4 lesions, and develop an efficient method to help patients avoid unnecessary biopsy.
methodsA total of 75 patients with breast diseases classified as BI-RADS 4 (45 with malignant lesions and 30 with benign lesions) were prospectively enrolled in this study. T1-weighted imaging (T1WI), T2WI, DWI, and syMRI were performed at 3.0 T. Relaxation time (T1 and T2), apparent diffusion coefficient (ADC), conventional MRI features, and clinical features were assessed. "T" represents the relaxation time value of the region of interest pre-contrast scanning, and "T+" represents the value post-contrast scanning. The rate of change in the T value between pre- and post-contrast scanning was represented by ΔT%.
resultsΔT1%, T2, ADC, age, body mass index (BMI), menopause, irregular margins, and heterogeneous internal enhancement pattern were significantly associated with a breast cancer diagnosis in the multivariable logistic regression analysis. Based on the above parameters, four models were established: model 1 (BI-RADS model, including all conventional MRI features recommended by BI-RADS lexicon), model 2 (relaxation time model, including ΔT1% and T2), model 3 [multi-parameter (mp)MRI model, including ΔT1%, T2, ADC, margin, and internal enhancement pattern], and model 4 (combined image and clinical model, including ΔT1%, T2, ADC, margin, internal enhancement pattern, age, BMI, and menopausal state). Among these, model 4 has the best diagnostic performance, followed by models 3, 2, and 1.
conclusionsThe mpMRI model with DCE-MRI, DWI, and syMRI is a robust tool for evaluating the malignancies in BI-RADS 4 lesions. The clinical features could further improve the diagnostic performance of the model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.